A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

Bibliography

• Benchimol S, Fuks A, Jothy S, Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;11:327-34
   Google Scholar
• Robbins PF, Eggensperger D, Qi CF, Schlom J. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53:892-7
   PubMed Web of Science ®Google Scholar
• Tendler A, Kaufman HL, Kadish AS. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum Pathol 2000;31:1357-62
   PubMed Web of Science ®Google Scholar
• Ilantzis C, DeMarte L, Screaton RA, Stanners CP. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 2002;4:151-63
   PubMed Web of Science ®Google Scholar
• Hostetter RB, Campbell DE, Chi KF, Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. Arch Surg 1990;125:300-4
   PubMed Web of Science ®Google Scholar
• Mori F, Giannetti P, Peruzzi D, A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther 2009;20:125-36
   PubMed Web of Science ®Google Scholar
• Cho HI, Kim HJ, Oh ST, Kim TG. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003;22:224-36
   PubMed Web of Science ®Google Scholar
• Babatz J, Rollig C, Lobel B, Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006;55:268-76
   PubMed Web of Science ®Google Scholar
• Madan RA, Bilusic M, Hodge JW, A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA [abstract]. ASCO Annual Meeting; 2011. p. 2604
   Google Scholar
• Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002;62:6944-51
   PubMed Web of Science ®Google Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4:575-88
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7
   PubMed Web of Science ®Google Scholar
• Kantor J, Abrams S, Irvine K, Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann N Y Acad Sci 1993;690:370-3
   PubMed Web of Science ®Google Scholar
• Kass E, Schlom J, Thompson J, Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-68
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM, Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31
   PubMed Web of Science ®Google Scholar
• Tsang KY, Zaremba S, Nieroda CA, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90
   PubMed Web of Science ®Google Scholar
• Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008;22:1064-70; discussion 1075, 1080–1081, 1084
   PubMed Web of Science ®Google Scholar
• Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009;11:37-42
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Cardenes H, Multi-institutional Phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-8
   PubMed Web of Science ®Google Scholar
• Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005;15:279-83
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Zaremba S, Barzaga E, Zhu M, Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9
   PubMed Web of Science ®Google Scholar
• Yokokawa J, Cereda V, Remondo C, Enhanced functionality of CD+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Omiya R, Ruiz M, Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Sako T, Shibao K, Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 2002;22:2437-42
   PubMed Web of Science ®Google Scholar
• Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86:417-23
   PubMed Web of Science ®Google Scholar
• Morse M, Niedzwiecki D, Marshall JL, Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls [abstract]. ASCO Annual Meeting; 2011. p-3557
   Google Scholar
• Lyerly H, Hobeika A, Niedzwiecki D, A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study [sbstract]. ASCO Annual Meeting; 2011. p. 2533
   Google Scholar
• von Mehren M, Arlen P, Gulley J, The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91
   PubMed Web of Science ®Google Scholar
• Fu T, Shen Y, Fujimoto S. Tumor-specific CD4+ suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-7
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-40
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-51
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74
   PubMed Web of Science ®Google Scholar
• Gulley J, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011;18:e150-7
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S, Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97
   PubMed Web of Science ®Google Scholar
• Goeckeler WF, Edwards B, Volkert WA, Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28:495-504
   PubMed Web of Science ®Google Scholar
• Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother 2006;7:1475-86
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer. ClinicalTrials.gov NCT00450619; Available from http://clinicaltrials.gov/ct2/show/NCT00450619?term=NCT00450619&rank=1
   Google Scholar